NYSE: NUSNu Skin Enterprises Inc Stock
$7.01+0.08 (+1.15%)
Updated Jan 17, 2025
NUS Price
$7.01
Fair Value Price
N/A
Market Cap
$348.47M
52 Week Low
$5.95
52 Week High
$19.30
P/E
-3.37x
P/B
0.49x
P/S
0.21x
PEG
N/A
Dividend Yield
2.57%
Revenue
$1.78B
Earnings
-$103.21M
Gross Margin
70.7%
Operating Margin
-4.92%
Profit Margin
-5.8%
Debt to Equity
1.24
Operating Cash Flow
$140M
Beta
0.77
Next Earnings
Feb 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NUS Overview
Nu Skin Enterprises, Inc. distributes beauty and wellness products in the U.S. and internationally. The company's skin care systems ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, ageLOC LumiSpa skin treatment and cleansing devices, and ageLOC Boost. It also offers other cosmetic and personal care products, LifePak nutritional supplements, ageLOC Meta nutritional supplements, skin care supplements, and weight management products. Nu Skin Enterprises was founded in 1984 and is headquartered in Provo, UT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NUS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Value
C
Growth
D
Momentum
C
Sentiment
C
Safety
B
Financials
B
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Household & Personal Product
Industry Rating
B
NUS
Ranked#6 of 25
Ranked#6 of 25
Be the first to know about important NUS news, forecast changes, insider trades & much more!
NUS News
Overview
Due Diligence Score
–
Industry Average (35)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NUS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NUS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NUS is good value based on its book value relative to its share price (0.49x), compared to the US Household & Personal Products industry average (7.02x)
P/B vs Industry Valuation
NUS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more NUS due diligence checks available for Premium users.
Valuation
NUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.37x
Industry
31.15x
Market
30.45x
NUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.49x
Industry
7.02x
NUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NUS's financial health
Profit margin
Revenue
$430.1M
Net Income
$8.3M
Profit Margin
1.9%
NUS's Earnings (EBIT) of -$87.38M... subscribe to Premium to read more.
Interest Coverage Financials
NUS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6B
Liabilities
$876.0M
Debt to equity
1.24
NUS's short-term assets ($653.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NUS's short-term assets ($653.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$31.4M
Investing
-$6.5M
Financing
-$28.8M
NUS's operating cash flow ($140.12M)... subscribe to Premium to read more.
Debt Coverage Financials
NUS vs Household & Personal Product Stocks
Nu Skin Enterprises Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.